NEOVACS S.A.

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer

France-based Neovacs SA has reached an inflection point with the biological endpoint and three out of four clinical endpoints being met in a Phase IIb study, as it paves the way for talks with regul

The table records clinical developments using data from Informa Pharma Intelligence’s Biomedtracker. It lists drugs for which an important event was recorded between November 4 and November 10, 2016,

IN VITRO DIAGNOSTICS Financings Vermillion Inc. Vermillion Inc. grossed $5.6mm through the private sale of 3.75mm common shares at $1.40 (a 6% premium). Investors also received five-year warrants